Definition and evaluation of mucosal healing in clinical practice

Digestive and Liver Disease

Volumn 45, Issue 12, 2013, Pages 969-977

  Mazzuoli, Silvia ^a   Guglielmi, Francesco W ^a   Antonelli, Elisabetta ^b   Salemme, Marianna ^c   Bassotti, Gabrio ^b   Villanacci, Vincenzo ^c  

^a San Nicola Pellegrino Hospital Trani   (Italy)

^b UNIVERSITY OF PERUGIA   (Italy)

^c Spedali Civili of Brescia ^*  (Italy)

Author keywords

Anti TNF ; CD; CDEIS; Endoscopic index of severity; IBD; Inflammation; Inflammatory bowel disease; MH; Mucosal healing; Pathology; SES CD; The Lemann score; UC; UCEIS

Indexed keywords

CLINICAL PRACTICE; CROHN DISEASE; ENDOSCOPY; HEALING; HISTOPATHOLOGY; HOSPITALIZATION; HUMAN; INTESTINE MUCOSA; PRIORITY JOURNAL; QUALITATIVE DIAGNOSIS; QUANTITATIVE DIAGNOSIS; REMISSION; REVIEW; ULCERATIVE COLITIS;

ANTI-TNFΑ; ANTIBODY AGAINST TUMOUR NECROSIS FACTOR Α; CD; CDEIS; CROHN'S DISEASE; CROHN'S DISEASE DIGESTIVE DAMAGE SCORE; CROHN'S DISEASE ENDOSCOPIC INDEX OF SEVERITY; ENDOSCOPIC INDEX OF SEVERITY; IBD; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; MH; MUCOSAL HEALING; PATHOLOGY; SES-CD; SIMPLE ENDOSCOPIC SCORE FOR CROHN'S DISEASE; THE LEMANN SCORE; UC; UCEIS; ULCERATIVE COLITIS; ULCERATIVE COLITIS ENDOSCOPIC INDEX OF SEVERITY;

ADRENAL CORTEX HORMONES; BIOLOGICAL THERAPY; COLITIS, ULCERATIVE; CROHN DISEASE; ENDOSCOPY, GASTROINTESTINAL; HUMANS; IMMUNOLOGIC FACTORS; INTESTINAL MUCOSA; SALICYLATES; SEVERITY OF ILLNESS INDEX; TERMINOLOGY AS TOPIC; WOUND HEALING;

EID: 84887208189     PISSN: 15908658     EISSN: 18783562     Source Type: Journal    
DOI: 10.1016/j.dld.2013.06.010     Document Type: Review

References (90)

1. Rutgeerts P., Vermiere S., Assche G.V. Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target. Gut 2007, 56:453-455.
2. Lichtenstein G.R., Ramsey D., Rubin D.T. Randomised clinical trial: delayed-release oral mesalazine 4.8g/day vs. 2.4g/day in endoscopic mucosal healing-ASCEND I and II combined analysis. Alimentary Pharmacology and Therapeutics 2011, 33:672-678.
3. Modigliani R., Mary J.Y., Simon J.F., et al. Clinical, biological, and endoscopic picture of Latest studies show that images taken with the CLE might offer information equivalent to conventional histology with a good correlation between CLE and histological results attacks of Crohn's disease. Evolution on prednisolone. Groupe d'Etude Therapeutique des Affections Inflammatoires Digestives. Gastroenterology 1990, 98:811-818.
4. D'Haens G., Geboes K., Rutgeerts P. Endoscopic and histologic healing of Crohn's ileo-colitis with azathioprine. Gastrointestinal Endoscopy 1999, 50:667-671.
5. Sandborn W.J., Kamm M.A., Lichtenstein G.R., et al. MMX Multi Matrix System mesalazine for the induction of remission in patients with mild-to-moderate ulcerative colitis: a combined analysis of two randomized, double-blind, placebo-controlled trials. Alimentary Pharmacology and Therapeutics 2007, 26:205-211.
6. Ardizzone S., Cassinotti A., Duca P., et al. Mucosal healing predicts late outcomes after the first course of corticosteroids for newly diagnosed ulcerative colitis. Clinical Gastroenterology and Hepatology 2011, 9:483-489.
7. Ardizzone S., Maconi G., Russo A., et al. Randomised controlled trial of azathioprine and 5-aminosalicylic acid for treatment of steroid dependent ulcerative colitis. Gut 2006, 55:47-53.
8. af Bjorkesten C.G., Nieminen U., Turunen U., et al. Endoscopic monitoring of infliximab therapy in Crohn's disease. Inflammatory Bowel Diseases 2011, 17:947e53.
9. Rutgeerts P., Van Assche G., Sandborn W.J., et al. Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology 2012, 142. 1102e11.e2.
10. Fischer A., Gluth M., Pape U.F., Wiedenmann B., Baumgart D.C. Adalimumab prevents barrier dysfunction and antagonizes distinct effects of TNF on tight junctions and signaling pathways in intestinal epithelial cells. American Journal of Physiology: Gastrointestinal and Liver Physiology 2013, 304(11):G970-G979.
11. De Chambrun G., Peryrin Biroulet L., Lemman M., Colombel J.F. Clinical Implications of mucosal healing for the management of IBD. Nature Reviews Gastroenterology & Hepatology 2010, 7:15-29.
12. Pineton de Chambrun G., Peyrin-Biroulet L., Lémann M., Colombel J.F. Clinical implications of mucosal healing for the management of IBD. Nature Reviews Gastroenterology & Hepatology 2010, 7:15-29.
13. Fiorino G., Cesarini M., Indriolo A., Malesci A. Mucosal healing in ulcerative colitis: where do we stand?. Current Drug Targets 2011, 12:1417-1423.
14. D'Haens G., Sandborn W.J., Feagan B.G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with ulcerative colitis. Gastroenterology 2007, 132:763-786.
15. William J., Sandborn W.J., Brian G., et al. A review of activity indices and efficacy end points for clinical trials of medical therapy in adults with Crohn's disease. Gastroenterology 2002, 122:512-530.
16. D'Haens G.R., Fedorak R., Lemann M., et al. Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohn's disease. Inflammatory Bowel Diseases 2009, 15:1599-1604.
17. Solberg I.C., Lygren I., Jahnsen J., Vatn M., Moum B. Mucosal healing after initial treatment may be a prognostic marker for long-term outcome in inflammatory bowel disease. Gut 2008, 57(Suppl. 2):A15.
18. D'Haens G., Norman M., Baert F., Hiele M. Endoscopic healing after infliximab treatment for Crohn's disease provides a longer time to relapse. Gastroenterology 2002, 122:100A.
19. Schnitzler F., Fidder H., Ferrante M., et al. Mucosal healing predicts long term outcome of maintenance therapy with infliximab in Crohn's disease. Inflammatory Bowel Diseases 2009, 15:1295-1301.
20. Froslie K.F., Jahnsen J., Moum B.A. Vatn Mucosal healing in inflammatory bowel disease: results from a Norwegian population-based cohort. Gastroenterology 2007, 33:412-422.
21. Casellas F., Barreiro de Acosta M., Robles V., et al. Mucosal healing restores normal health and quality of life in patients with inflammatory bowel disease. European Journal of Gastroenterology & Hepatology 2012, 24:762-769.
22. Actis G.C., Pellicano R., David E., et al. Azathioprine, mucosal healing in ulcerative colitis, and the chemoprevention of colitic cancer: a clinical-practice-based forecast. Inflammation & Allergy Drug Targets 2010, 9:6e9.
23. Magro F., Portella F. Management of inflammatory bowel disease with infliximab and other anti-tumor necrosis factor alpha therapies. Bio Drugs 2010, 24(Suppl 1):3-14.
24. Peyrin-Biroulet L., Ferrante M., Magro F., et al. Results from the 2nd Scientific Workshop of the ECCO (I): impact of mucosal healing on the course of inflammatory bowel disease. Journal of Crohn's and Colitis 2011, 5:477-483.
25. David S., Fefferman, Farrell Richard J. Endoscopy in inflammatory bowel disease: indications, surveillance, and use in clinical practice. Clinical Gastroenterology and Hepatology 2005, 3:11-24.
26. Delpre G., Avidor I., Steinherz R., Kadish U., Ben-Bassat M. Ultrastructural abnormalities in endoscopically and histologically normal and involved colon in ulcerative colitis. American Journal of Gastroenterology 1989, 84:1038-1046.
27. Neumann H., Vieth M., Atreya R., et al. Prospective evaluation of the learning curve of confocal laser endomicroscopy in patients with IBD. Histology and Histopathology 2011, 26:867e72.
28. Neumann H., Neurath M.F., Mudter J. New endoscopic approaches in IBD. World Journal of Gastroenterology 2011, 17:63e8.
29. Kiesslich R., Goetz M., Lammersdorf K., et al. Chromoscopyguided endomicroscopy increases the diagnostic yield of intraepithelial neoplasia in ulcerative colitis. Gastroenterology 2007, 132:874e82.
30. Li C.Q., Xie X.J., Yu T., et al. Classification of inflammation activity in ulcerative colitis by confocal laser endomicroscopy. American Journal of Gastroenterology 2010, 105(6):1391-1396.
31. Watanabe O., Ando T., Maeda O., et al. Confocal endomicroscopy in patients with ulcerative colitis. Journal of Gastroenterology and Hepatology 2008, 23(S2):S286-S290.
32. Kudo T., Matsumoto T., Esaki M., Yao T., Iida M. Mucosal vascular pattern in ulcerative colitis: observations using narrow band imaging colonoscopy with special reference to histologic inflammation. International Journal of Colorectal Disease 2009, 24:495-501.
33. Salvatori F., Siciliano S., Maione F., et al. Confocal laser endomicroscopy in the Study of Colonic Mucosa in IBD Patients: a review. Gastroenterology Research and Practice 2012, 2012:525098.
34. Nishio Y., Ando T., Maeda O., et al. Pit patterns in rectal mucosa assessed by magnifying colonoscope are predictive of relapse in patients with quiescent ulcerative colitis. Gut 2006, 55:1768-1773.
35. Fujiya M., Saitoh Y., Nomura M., et al. Minute findings by magnifying colonoscopy are useful for the evaluation of ulcerative colitis. Gastrointestinal Endoscopy 2002, 56(4):535-542.
36. Matsumoto T., Kudo T., Jo Y., Esaki M., Yao T., Iida M. Magnifying colonoscopy with narrow band imaging system for the diagnosis of dysplasia in ulcerative colitis: a pilot study. Gastrointestinal Endoscopy 2007, 66:957-965.
37. Hlavaty T., Huorka M., Koller T., et al. Colorectal cancer screening in patients with ulcerative and Crohn's colitis with use of colonoscopy, chromoendoscopy and confocal endomicroscopy. European Journal of Gastroenterology & Hepatology 2011, 23:680-689.
38. van den Broek F.J., Fockens P., van Eeden S., et al. Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomized comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and evaluation of narrow-band imaging for classification of lesions. Gut 2008, 57:1083-1089.
39. Neumann H., Vieth M., Atreya R., et al. Assessment of Crohn's disease activity by confocal laser endomicroscopy. Inflammatory Bowel Diseases 2012, [Published Online First: 16 February 2012]. 10.1002/ibd.22907.
40. Kiesslich R., Duckworth C.A., Moussata D., et al. Local barrier dysfunction identified by confocal laser endomicroscopy predicts relapse in inflammatory bowel disease. Gut 2012, 61:114653.
41. http://clinicaltrials.gov/ct2/show/NCTO1417728.
42. Bourreille A., Ignjatovic A., Aabakken L., et al. Role of small bowel endoscopy in the management of patients with inflammatory bowel disease: an international OMED-ECCO consensus. Endoscopy 2009, 41:618-637.
43. Mary J.Y., Modigliani R. Development and validation of an endoscopic index of the severity for Crohn's disease: a prospective multicenter study. Groupe d'Etudes Therapeutiques des Affections Inflammatoires du Tube Digestif (GETAID). Gut 1989, 30:983-989.
44. Daperno M., D'Haens G., Assche G.V., et al. Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CD. Gastrointestinal Endoscopy 2004, 60:505-512.
45. Rutgeerts P. Review article: recurrence of Crohn's disease after surgery-the need for treatment of new lesions. Alimentary Pharmacology and Therapeutics 2006, 24:29-32.
46. Rutgeerts P., Geboes K., Vantrappen G., Beyls J., Kerremans R., Hiele M. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990, 99:956-963.
47. Rutgeerts P., Geboes K., Vantrappen G., Kerremans R., Coenegrachts J.L., Coremans G. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 2004, 25:665-672.
48. Caprilli R. European evidence based consensus on the diagnosis and management of Crohn's disease: special situation. Gut 2006, 55(Suppl. 1):i36-i58.
49. Rutgeerts P., Van Assche G. What is the role of endoscopy in the postoperative management of Crohn's disease?. Inflammatory Bowel Diseases 2008, 14(Suppl. 2):S179-S180.
50. Pariente B., Cosnes J., Danese S., et al. Development of the Crohn's disease digestive damage score, the Lémann score. Inflammatory Bowel Diseases 2011, 17:1415-1422.
51. Truelove S.C., Witts L.J. Cortisone in ulcerative colitis; final report on a therapeutic trial. British Medical Journal 1955, 2:1041-1048.
52. Baron J.H., Connell A.M., Lennard-Jones J.E. Variation between observers in describing mucosal appearances in proctocolitis. British Medical Journal 1964, 1:89-92.
53. Powell-Tuck J., Bown R.L., Lennard-Jones J.E. A comparison of oral prednisolone given as single or multiple daily doses for active proctocolitis. Scandinavian Journal of Gastroenterology 1978, 13:971-976.
54. Sutherland L.R., Martin F., Greer S., et al. 5-Aminosalicylic acid enema in the treatment of distal ulcerative colitis, proctosigmoiditis and proctitis. Gastroenterology 1987, 92:1894-1898.
55. Rachmilewitz D. Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of ulcerative colitis: randomized trials. British Medical Journal 1989, 298:82-86.
56. Schoepfer A.M., Beglinger C., Straumann A., Trummler M., Renzulli P., Seilbond F. Ulcerative Colitis: correlation of the Rachmilewitz Endoscopic Activity Index with fecal calprotectin, clinical activity, C-reactive protein and blood leukocytes. Inflammatory Bowel Diseases 2009, 15:1851-1858.
57. Schroeder K.W., Tremaine W.J., Ilstrup D.M. Coated oral 5-aminosalicylic acid therapy for mildly to moderately active ulcerative colitis. A randomizes study. New England Journal of Medicine 1987, 317:1625-1629.
58. Samuel S., Loftus E.V., Bruining D.H., et al. Validation of the ulcerative colitis endoscopic index of severity (UCEIS) and its correlation with clinical indices and laboratory measures of disease activity. Gastroenterology 2011, 140:A851.
59. Samuel S., Bruining D.H., Loftus E.V., et al. Validation of the ulcerative colitis colonoscopic index of severity and its correlation with disease activity measures. Clinical Gastroenterology and Hepatology 2013, 11:49-54.
60. Villanacci V., Manenti S., Antonelli E., Chiudinelli M., Giuliano V., Bassotti G. Non-IBD colitides: clinically useful histopathological clues. Revista Espanola de Enfermedades Digestivas 2011, 103:366-372.
61. Stange E.F., Travis S.P., Vermeire S., et al. Warren BF; for the European Crohn's and Colitis Organization (ECCO). European evidence-based Consensus on the diagnosis and management of ulcerative colitis: Definitions and diagnosis. Journal of Crohns and Colitis 2008, 2:1-23.
62. Stange E.F., Travis S.P., Vermeire S., et al. European evidence based consensus on the diagnosis and management of Crohn's disease: definitions and diagnosis. Gut 2006, 55(Suppl. 1):i1-i15.
63. Geboes K., Dalle I. Influence of treatment on morphological features of mucosal inflammation. Gut 2002, 50(Suppl. 3):III37-III42.
64. Jenkins D., Balsitis M., Gallivan S., et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. Journal of Clinical Pathology 1997, 50:93-105.
65. Seldenrijk C.A., Morson B.C., Meuwissen S.G., Schipper N.W., Lindeman J., Meijer C.J. Histopathological evaluation of colonic mucosal biopsy specimens in chronic inflammatory bowel disease: diagnostic implications. Gut 1991, 32:1514-1520.
66. Schumacher G., Kollberg B., Sandstedt B. A prospective study of first attacks of inflammatory bowel disease and infectious colitis. Scandinavian Journal of Gastroenterology 1994, 29:318-332.
67. Bitton A., Peppercorn M.A., Antonioli D.A., et al. Clinical, biological, and histologic parameters as predictors of relapse in ulcerative colitis. Gastroenterology 2001, 120:13-20.
68. Rosenberg L., Nanda K.S., Zenlea T., et al. Histologic markers of inflammation in patients with ulcerative colitis in clinical remission. Clinical Gastroenterology and Hepatology 2013, 11(8):991-996.
69. Kruis W., Bar-Meir S., Feher J., et al. The optimal dose of 5-aminosalicylic acid in active ulcerative colitis: a dose-finding study with newly developed mesalamine. Clinical Gastroenterology and Hepatology 2003, 1:36-43.
70. Mansfield J.C., Giaffer M.H., Cann P.A., McKenna D., Thornton P.C., Holdsworth C.D. A double-blind comparison of balsalazide, 6.75g, and sulfasalazine, 3g, as sole therapy in the management of ulcerative colitis. Alimentary Pharmacology and Therapeutics 2002, 16:69-77.
71. Kruis W., Kiudelis G., Rácz I., et al. International Salofalk OD Study Group Once daily versus three times daily mesalazine granules in active ulcerative colitis: a double-blind, double-dummy, randomized, non-inferiority trial. Gut 2009, 58:233-240.
72. Prantera C., Viscido A., Biancone L., Francavilla A., Giglio L., Campieri M. A new oral delivery system for 5-ASA: preliminary clinical findings for MMx. Inflammatory Bowel Diseases 2005, 11:421-427.
73. Floren C.H., Benoni C., Willen R. Histologic and colonoscopic assessment of disease extension in ulcerative colitis. Scandinavian Journal of Gastroenterology 1987, 22:459-462.
74. Malchow H., Gertz B. A new mesalazine foam enema (Claversal Foam) compared with a standard liquid enema in patients with active distal ulcerative colitis. Alimentary Pharmacology and Therapeutics 2002, 16:415-423. CLAFOAM Study group.
75. Lee F.I., Jewell D.P., Mani V., et al. A randomized trial comparing mesalazine and prednisolone foam enemas in patients with acute distal ulcerative colitis. Gut 1996, 38:229-233.
76. Regueiro M., Loftus E.V., Steinhart A.H., Cohen R.D. Medical management of left-sided ulcerative colitis and ulcerative proctitis: critical evaluation of therapeutic trials. Inflammatory Bowel Diseases 2006, 12:979-994.
77. Truelove S.C. Treatment of ulcerative colitis with local hydrocortisone hemisuccinate sodium. A report on a controlled therapeutic trial. British Medical Journal 1958, 2:1072-1077.
78. Sandborn W.J., Van O.E.C., Zins B.J., Tremaine W.J., Mays D.C., Lipsky J.J. An intravenous loading dose of azathioprine decreases the time to response in patients with Crohn's disease. Gastroenterology 1995, 109:1808-1817.
79. D'Haens G., Geboes K., Ponette E., Penninckx F., Rutgeerts P. Healing of severe recurrent ileitis with azathioprine therapy in patients with Crohn's disease. Gastroenterology 1997, 112:1475-1481.
80. D'Haens G., Geboes K., Rutgeerts P. Endoscopic and histologic healing of Crohn's (ileo-) colitis with azathioprine. Gastrointestinal Endoscopy 1999, 50:667-671.
81. D'Haens G., Geboes K., Peeters M., Baert F., Penninckx F., Rutgeerts P. Early lesions caused by infusion of intestinal contents in excluded ileum in Crohn's disease. Gastroenterology 1998, 114:262-267.
82. Mantzaris G.J., Christidou A., Sfakianakis M., et al. Azathioprine is superior to budesonide in achieving and maintaining mucosal healing and histologic remission in steroid-dependent Crohn's disease. Inflammatory Bowel Diseases 2009, 15:375-382.
83. Kozarek R.A., Patterson D.J., Gelfand M.D., Botoman V.A., Ball T.J., Wilske K.R. Methotrexate induces clinical and histologic remission in patients with refractory inflammatory bowel disease. Annals of Internal Medicine 1989, 110:353-356.
84. Laharie D., Reffet A., Belleannée G., et al. Mucosal healing with methotrexate in Crohn's disease: a prospective comparative study with azathioprine and infliximab. Alimentary Pharmacology and Therapeutics 2011, 33:714-721.
85. D'Haens G., Van Deventer S., Van Hogezand R., et al. Endoscopic and histological healing with infliximab anti-tumor necrosis factor antibodies in Crohn's disease: a European multicenter trial. Gastroenterology 1999, 116:1029-1034.
86. Baert F.J., D'Haens G.R., Peeters M., et al. Tumor necrosis factor alpha antibody (infliximab) therapy profoundly down-regulates the inflammation in Crohn's ileocolitis. Gastroenterology 1999, 116:22-28.
87. D'Haens G., Swijsen C., Noman M., et al. Etanercept in the treatment of active refractory Crohn's disease: a single-center pilot trial. American Journal of Gastroenterology 2001, 96:2564-2568.
88. Hassan C., Ierardi E., Burattini O., et al. Tumour necrosis factor alpha down-regulation parallels inflammatory regression in ulcerative colitis patients treated with infliximab. Digestive and Liver Disease 2007, 39:811-817.
89. Fratila O.C., Craciun C. Ultrastructural evidence of mucosal healing after infliximab in patients with ulcerative colitis. Journal of Gastrointestinal and Liver Diseases 2010, 19:147-153.
90. Villanacci V., Antonelli E., Geboes K., Casella G., Bassotti G. Histological healing in inflammatory bowel disease: a still unfulfilled promise. World Journal of Gastroenterology 2013, 19:968-978.